Project Grant R21CA308920
Award Date 7/1/26
Completion Date 6/30/28
Dollars Obligated $435K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
New York, NY 10065, USA
Similar Awards
- Federal Project Grant Award Summary Weill Medical College of Cornell University received a $204,027 project grant from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396), effective August 1, 2025 through July 31, 2030. This award supports the development and application of advanced single-cell and spatial technologies designed to link clonal genotypes with phenotypes during cancer evolution. The project addresses a critical gap in cancer research by...
- Federal Project Grant Award Summary Weill Medical College of Cornell University received a $472,730 project grant award from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396), effective August 1, 2025, through July 31, 2030. This five-year project investigates the role of the tumor suppressor KEAP1 (Kelch-like ECH-associated protein 1) in antitumor immunity, with specific focus on understanding how loss-of-function KEAP1 mutations contribute to immune...
- Federal Project Grant Award Summary Weill Medical College of Cornell University received a $401,829 Project Grant award from the National Cancer Institute under the Cancer Biology Research program (CFDA 93.396), effective September 1, 2025, through August 31, 2028. The award funds the development of innovative single-cell molecular footprinting methodologies to map chromatin-associated protein activity in cancer cells. Specifically, the research introduces Docking & Deamination Plus...
- Federal Project Grant Award Summary The National Cancer Institute awarded Weill Medical College of Cornell University a Project Grant totaling $1,312,608 under the Cancer Biology Research program (CFDA 93.396), effective July 10, 2025, with completion targeted for April 30, 2030. This award supports fundamental research into signal transduction to p70 S6 kinase 1 (S6K1) and mechanistic target of rapamycin complex 1 (mTORC1) signaling pathways in cancer cells. The primary research objective is to...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded a $703,423 Project Grant under the Cancer Biology Research program (CFDA 93.396) to Weill Medical College of Cornell University, effective June 1, 2026 through May 31, 2031. This five-year award supports fundamental research to identify and validate therapeutic targets that mitigate immune-related adverse events (IRAEs) associated with immune checkpoint blockade (ICB) immunotherapies while preserving anti-tumor...
- Federal Grant Award Summary The National Cancer Institute awarded $716,183 to Weill Medical College of Cornell University on May 13, 2026, under the Cancer Treatment Research program (CFDA 93.395) to support research on next-generation chimeric antigen receptor (CAR) T-cell therapies for cancer treatment. The five-year project, concluding April 30, 2031, will deliver research and development services focused on interrogating how immune regulatory ligands affect CAR-T cell function and...
- Federal Grant Award Summary Weill Medical College of Cornell University received a $198,164 Project Grant award from the National Cancer Institute under the Cancer Research Manpower program (CFDA 93.398) on September 26, 2025, with a completion date of April 6, 2027. This award funds investigator-initiated research focused on elucidating the role of the APOBEC3 (A3) family of cytosine deaminases in driving genomic instability and somatic mutagenesis in lung cancer. The project involves...
- Federal Project Grant Award Summary Weill Medical College of Cornell University received a $169,291 Project Grant award from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) effective May 1, 2026, through April 30, 2028. The award funds research to characterize the cooperative role of E2F1 and interacting proteins in driving advanced prostate cancer, with particular focus on understanding neuroendocrine prostate cancer (NEPC) progression....
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded Weill Medical College of Cornell University a $694,133 Project Grant under the Cancer Biology Research program (CFDA 93.396) on May 14, 2026, to support fundamental research on axonal control of tumor progression in melanoma. The research will investigate how sympathetic nervous system axons and their neurotransmitter signaling inhibit melanoma growth through interactions with immune cells in the tumor...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded Columbia University's Health Sciences Division a $501,422 Project Grant under the Cancer Biology Research program (CFDA 93.396) commencing May 1, 2026, with completion targeted for April 30, 2031. This award supports fundamental research to advance understanding of synthetic lethal (SL) vulnerabilities in specific cancer subtypes, with the ultimate objective of developing novel precision oncology therapeutics. The research...